Asterias Biotherapeutics Inc (NYSEMKT:AST) insider Edward Wirth sold 3,415 shares of the firm’s stock in a transaction that occurred on Thursday, October 6th. The shares were sold at an average price of $4.12, for a total value of $14,069.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Edward Wirth also recently made the following trade(s):

  • On Friday, September 9th, Edward Wirth sold 14,760 shares of Asterias Biotherapeutics stock. The shares were sold at an average price of $3.52, for a total value of $51,955.20.

Shares of Asterias Biotherapeutics Inc (NYSEMKT:AST) opened at 3.88 on Wednesday. The firm’s market cap is $176.22 million. Asterias Biotherapeutics Inc has a one year low of $2.30 and a one year high of $5.75. The stock’s 50 day moving average price is $3.75 and its 200 day moving average price is $3.50.

Asterias Biotherapeutics (NYSEMKT:AST) last posted its quarterly earnings data on Monday, August 15th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.07. The firm had revenue of $1.53 million for the quarter, compared to analyst estimates of $1.14 million. On average, equities analysts anticipate that Asterias Biotherapeutics Inc will post ($0.73) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Asterias Biotherapeutics (NYSEMKT:AST)

A number of analysts have issued reports on the company. Zacks Investment Research raised Asterias Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 19th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Asterias Biotherapeutics in a report on Sunday, September 11th. Finally, FBR & Co reaffirmed a “buy” rating on shares of Asterias Biotherapeutics in a report on Wednesday, August 31st. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $7.75.

Several hedge funds and other institutional investors have recently bought and sold shares of AST. Bank of New York Mellon Corp boosted its position in Asterias Biotherapeutics by 55.7% in the second quarter. Bank of New York Mellon Corp now owns 54,406 shares of the company’s stock valued at $131,000 after buying an additional 19,469 shares in the last quarter. BlackRock Investment Management LLC boosted its position in Asterias Biotherapeutics by 100.7% in the second quarter. BlackRock Investment Management LLC now owns 73,307 shares of the company’s stock valued at $176,000 after buying an additional 36,782 shares in the last quarter. State Street Corp boosted its position in Asterias Biotherapeutics by 5.5% in the first quarter. State Street Corp now owns 96,218 shares of the company’s stock valued at $452,000 after buying an additional 5,000 shares in the last quarter. Sabby Management LLC purchased a new position in Asterias Biotherapeutics during the second quarter valued at $741,000. Finally, BlackRock Fund Advisors boosted its position in Asterias Biotherapeutics by 114.4% in the second quarter. BlackRock Fund Advisors now owns 586,720 shares of the company’s stock valued at $1,408,000 after buying an additional 313,067 shares in the last quarter.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Stock Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related stocks with our FREE daily email newsletter.